Attachment II - Page 1 
f 
8810-001* 
j 9007-002*’ b 
I 
s 
! 9007-003 
j 9102-004* 
9105-005* 
9105-006* 
9105-007* 
9105-008 
9105-009* 
9110-010* 
9110-011 
91104)12* 
HUMAN GENE TRANSFER PROTOCOLS 
(M) Rosenberg, Steven A., National Institutes of Health, Bethesda, Maryland; The Treatment of Patients with Advanced Cancer 
Using Cyclophosphamide , Interleukin-2 and Tumor Infiltrating Lymphocytes. 
RAC Approval: 10-3-88/NIH Approval: 3-2-89 
Minor Modification: 3-30-90 
(T) Blaese, R. Michael, National Institutes of Health, Bethesda, Maryland; Treatment of Severe Combined Immune Deficiency (SCID) 
due to Adenosine Deaminase (ADA) Deficiency with CD34(+) Selected Autologous Hematopoietic Stem Cells 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 
Major Amendment/RAC Approval: 2-10-92 
Major Amendment/NIH Approval: 4-22-92 
Minor Modification: 4-21-93 
Minor Modification: 6-7-93 
CO Rosenberg, Steven A, National Institutes of Health, Bethesda, Maryland; Gene Therapy of Patients with Advanced Cancer Using 
Tumor Infiltrating Lymphocytes Transduced with the Gene Coding for Tumor Necrosis Factor. 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 
(M) Brenner, Malcolm K.; Mirro, Joseph; Hurwitz, Craig; Santana, Victor; and Ihle, James, St Jude Children’s Research Hospital, 
Memphis, Tennessee; Autologous Bone Marrow Transplant for Children with Acute Myelogenous Leukemia in First Complete 
Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse. 
RAC Approval: 2-4-91/NIH Approval: 7-12-91 
Minor Modification: 11-91 
(M) Brenner, Malcolm K.; Mirro, Joseph; Santana, Victor, and Ihle, James, St Jude Children’s Research Hospital, Memphis, 
Tennessee; A Phase I /II Trial of High Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Stage D 
Neuroblastoma in First Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism 
of Relapse. 
RAC Approval: 5-31-91/NIH Approval: 7-12-91 
Minor Modification: 11-91 
(M) Brenner, Malcolm K.; Mirro, Joseph; Santana, Victor, and Ihle, James, St Jude Children’s Research Hospital, Memphis, 
Tennessee; A Phase II Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of 
Relapse /Refractory Neuroblastoma Without Apparent Bone Marrow Involvement. 
RAC Approval: 5-31-91/NIH Approval: 7-12-91 
Minor Modification: 11-91 
(M) Deisseroth, Albert B., M.D. Anderson Cancer Research Center, Houston, Texas; Autologous Bone Marrow Transplantation for 
Chronic Myelogenous Leukemia in which Retroviral Markers are Used to Discriminate between Relapse which Arises from Systemic 
Disease Remaining qfter Preparative Therapy Versus Relapse due to Residual Leukemic Cells in Autologous Marrow: A Pilot Trial. 
RAC Approval: 5-31-91/NIH Approval: 7-12-91 
Minor Modification: 4-19-93 
(M) Ledley, Fred D.; Woo, Savio; Ferry, George; and Hartwell, Whigennand, Baylor College of Medicine, Houston, Texas; 
Hepatocellular Transplantation in Acute Hepatic Failure and Targeting Genetic Markers to Hepatic Cells. 
RAC Approval: 5-3G-91/NIH Approval: 7-12-91 
(M) Lotze, Michael T., University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Administration of Interieukin-2 
and Tumor Infiltrating Lymphocytes to Patients with Melanoma. 
RAC Approval: 5-30-91/NIH Approval: 1-17-92 
Minor Modification: 11-30-92 
(T) Rosenberg, Steven A, National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients Using Autologous 
Cancer Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (INF). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 
Minor Modification: 7-9-92 
(T) Rosenberg, Steven A, National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients Using Autologous 
Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (IL-2). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 
(T) Wilson, James M., University of Pennsylvania, Philadelphia, Pennsylvania; Ex Vivo Gene Therapy of Familial 
Hypercholesterolemia. 
RAC Approval: 10-8-91/NIH Approval: 11-14-91 
Minor Modification: 12-3-92 
Minor Modification: 8-18-93 
Recombinant DNA Research, Volume 18 
[573] 
